Resolvin T-series reduce neutrophil extracellular traps
暂无分享,去创建一个
D. Irimia | C. Serhan | B. Spur | N. Chiang | M. Sakuma | Ana R Rodriguez | Miyuki Sakuma
[1] V. Wahn,et al. Myeloperoxidase is required for neutrophil extracellular trap formation: implications for innate immunity. , 2011, Blood.
[2] C. Serhan,et al. The need for precision nutrition, genetic variation and resolution in Covid-19 patients , 2021, Molecular Aspects of Medicine.
[3] F. Fattahi,et al. New strategies for treatment of infectious sepsis , 2019, Journal of leukocyte biology.
[4] C. Parkos,et al. Role of negative regulation of immune signaling pathways in neutrophil function , 2017, Journal of leukocyte biology.
[5] P. Delvenne,et al. Neutrophil extracellular traps infiltrate the lung airway, interstitial, and vascular compartments in severe COVID-19 , 2020, The Journal of experimental medicine.
[6] D. Zeldin,et al. Resolvin Infectious Inflammation by Targeting the Host Response. , 2015, The New England journal of medicine.
[7] T. Renné,et al. Persistent endotheliopathy in the pathogenesis of long COVID syndrome , 2021, Journal of Thrombosis and Haemostasis.
[8] M. Balaan,et al. Acute Respiratory Distress Syndrome , 2016, Critical care nursing quarterly.
[9] W. Maixner,et al. Neuroimmune modulation of pain and regenerative pain medicine. , 2020, The Journal of clinical investigation.
[10] Fuquan Wang,et al. Resolvin D1 attenuates ventilator-induced lung injury by reducing HMGB1 release in a HO-1-dependent pathway. , 2019, International immunopharmacology.
[11] A. Roy,et al. Atorvastatin and Aspirin as Adjuvant Therapy in Patients with SARS-CoV-2 Infection: A structured summary of a study protocol for a randomised controlled trial , 2020, Trials.
[12] P. Kubes,et al. Neutrophil recruitment and function in health and inflammation , 2013, Nature Reviews Immunology.
[13] C. Serhan,et al. 15-epi-lipoxin A4 inhibits myeloperoxidase signaling and enhances resolution of acute lung injury. , 2009, American journal of respiratory and critical care medicine.
[14] W. Nauseef,et al. Neutrophils at work , 2014, Nature Immunology.
[15] Lydia M. Roberts,et al. Cutting Edge: Severe SARS-CoV-2 Infection in Humans Is Defined by a Shift in the Serum Lipidome, Resulting in Dysregulation of Eicosanoid Immune Mediators , 2020, The Journal of Immunology.
[16] K. Huber,et al. Neutrophil Extracellular Trap Degradation by Differently Polarized Macrophage Subsets , 2020, Arteriosclerosis, thrombosis, and vascular biology.
[17] N. McElvaney,et al. Dysregulated plasma lipid mediator profiles in critically ill COVID-19 patients , 2021, PloS one.
[18] M. Iezzi,et al. Resolvin D1 and D2 reduce SARS‐CoV‐2‐induced inflammatory responses in cystic fibrosis macrophages , 2021, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[19] B. Mallavia,et al. Maladaptive role of neutrophil extracellular traps in pathogen-induced lung injury. , 2018, JCI insight.
[20] Axel Haverich,et al. Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19. , 2020, The New England journal of medicine.
[21] C. Nathan. Neutrophils and COVID-19: Nots, NETs, and knots , 2020, The Journal of experimental medicine.
[22] R. Hawkins,et al. Resolvin D1 decreases abdominal aortic aneurysm formation by inhibiting NETosis in a mouse model , 2018, Journal of vascular surgery.
[23] Lydia M. Roberts,et al. Severe SARS-CoV-2 infection in humans is defined by a shift in the serum lipidome resulting in dysregulation of eicosanoid immune mediators , 2020, medRxiv.
[24] Ira Tabas,et al. Inflammation and its resolution in atherosclerosis: mediators and therapeutic opportunities , 2019, Nature Reviews Cardiology.
[25] O. Soehnlein,et al. Neutrophils as regulators of cardiovascular inflammation , 2020, Nature Reviews Cardiology.
[26] J. Filep. Leukocytes in Inflammation, Resolution of Inflammation, Autoimmune Diseases and Cancer , 2021, Cells.
[27] T. V. Van Dyke. Pro-resolving mediators in the regulation of periodontal disease. , 2017, Molecular aspects of medicine.
[28] P. Kubes,et al. An emerging role for neutrophil extracellular traps in noninfectious disease , 2017, Nature Medicine.
[29] S. Fagan,et al. Resolvin D2 restores neutrophil directionality and improves survival after burns , 2013, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[30] M. Perretti,et al. Immune resolution mechanisms in inflammatory arthritis , 2017, Nature Reviews Rheumatology.
[31] X. de la Rosa,et al. Resolvin D4 attenuates the severity of pathological thrombosis in mice. , 2019, Blood.
[32] G. Fredman,et al. Resolvin D1 Enhances Necroptotic Cell Clearance Through Promoting Macrophage Fatty Acid Oxidation and Oxidative Phosphorylation. , 2021, Arteriosclerosis, thrombosis, and vascular biology.
[33] K. Tracey,et al. HMGB1–C1q complexes regulate macrophage function by switching between leukotriene and specialized proresolving mediator biosynthesis , 2019, Proceedings of the National Academy of Sciences.
[34] Charles N Serhan,et al. Resolvins in inflammation: emergence of the pro-resolving superfamily of mediators. , 2018, Journal of Clinical Investigation.
[35] N. Flamand,et al. High levels of eicosanoids and docosanoids in the lungs of intubated COVID‐19 patients , 2021, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[36] Nuraini Yasmin Kusumawardhani,et al. In-hospital use of statins is associated with a reduced risk of mortality in coronavirus-2019 (COVID-19): systematic review and meta-analysis , 2021, Pharmacological Reports.
[37] J. M. Crawford,et al. Targeting potential drivers of COVID-19: Neutrophil extracellular traps , 2020, The Journal of experimental medicine.
[38] C. Serhan,et al. Elucidation of novel 13-series resolvins that increase with atorvastatin and clear infections , 2015, Nature Medicine.
[39] Takao Shimizu,et al. Leukotriene receptors as potential therapeutic targets , 2018, The Journal of clinical investigation.
[40] D. Wagner,et al. Peptidylarginine deiminase 4: a nuclear button triggering neutrophil extracellular traps in inflammatory diseases and aging , 2018, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[41] Michael S. Goldberg,et al. Neutrophil extracellular traps produced during inflammation awaken dormant cancer cells in mice , 2018, Science.
[42] D. Panigrahy,et al. Resolution of inflammation: An organizing principle in biology and medicine. , 2021, Pharmacology & therapeutics.
[43] C. Serhan,et al. Identification of resolvin D2 receptor mediating resolution of infections and organ protection , 2015, The Journal of experimental medicine.
[44] K. Tarte,et al. Impaired efferocytosis and neutrophil extracellular trap clearance by macrophages in ARDS , 2018, European Respiratory Journal.
[45] W. Nauseef. Isolation of human neutrophils from venous blood. , 2014, Methods in molecular biology.
[46] John Savill,et al. Resolution of inflammation: the beginning programs the end , 2005, Nature Immunology.
[47] D. Gilroy,et al. Proresolving lipid mediators and mechanisms in the resolution of acute inflammation. , 2014, Immunity.
[48] B. Spur,et al. First total synthesis of the pro-resolving lipid mediator 7(S),12(R),13(S)-Resolvin T2 and its 13(R)-epimer. , 2020, Tetrahedron letters.
[49] C. Serhan,et al. Specialized pro-resolving mediator network: an update on production and actions. , 2020, Essays in biochemistry.
[50] M. Surette,et al. A Novel Mechanism of Rapid Nuclear Neutrophil Extracellular Trap Formation in Response to Staphylococcus aureus , 2010, The Journal of Immunology.
[51] Gavin Thomas,et al. Disrupted Resolution Mechanisms Favor Altered Phagocyte Responses in COVID-19 , 2021, Circulation research.
[52] B. Fadeel,et al. Macrophage Clearance of Neutrophil Extracellular Traps Is a Silent Process , 2013, The Journal of Immunology.
[53] B. Levy,et al. Aspirin-triggered resolvin D1 reduces pneumococcal lung infection and inflammation in a viral and bacterial coinfection pneumonia model. , 2017, Clinical science.
[54] S. Colgan. Resolvins resolve to heal mucosal wounds , 2020, Proceedings of the National Academy of Sciences.
[55] D. Gilroy,et al. Resolution-phase macrophages possess a unique inflammatory phenotype that is controlled by cAMP , 2008, Blood.
[56] C. Serhan,et al. Specific lipid mediator signatures of human phagocytes: microparticles stimulate macrophage efferocytosis and pro-resolving mediators. , 2012, Blood.
[57] T. Kohlsdorf,et al. Inflammasomes are activated in response to SARS-CoV-2 infection and are associated with COVID-19 severity in patients , 2020, The Journal of experimental medicine.
[58] Miriam Merad,et al. Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages , 2020, Nature Reviews Immunology.
[59] D. Wagner,et al. Neutrophil histone modification by peptidylarginine deiminase 4 is critical for deep vein thrombosis in mice , 2013, Proceedings of the National Academy of Sciences.
[60] B. Spur,et al. First total syntheses of the pro-resolving lipid mediators 7(S),13(R),20(S)-Resolvin T1 and 7(S),13(R)-Resolvin T4. , 2020, Tetrahedron letters.
[61] V. Mirakaj. Immune cells—A curse and a blessing! , 2021, The Journal of experimental medicine.
[62] P. Saldiva,et al. SARS-CoV-2–triggered neutrophil extracellular traps mediate COVID-19 pathology , 2020, The Journal of experimental medicine.
[63] R. Colas,et al. 13-Series resolvins mediate the leukocyte-platelet actions of atorvastatin and pravastatin in inflammatory arthritis , 2017, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[64] M. Perretti,et al. Resolvin D2 is a potent regulator of leukocytes and controls microbial sepsis , 2009, Nature.
[65] J. Filep,et al. 15-Epi-LXA4 and 17-epi-RvD1 restore TLR9-mediated impaired neutrophil phagocytosis and accelerate resolution of lung inflammation , 2020, Proceedings of the National Academy of Sciences.
[66] J. Schwarze,et al. The role of pro-resolution lipid mediators in infectious disease , 2014, Immunology.